Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study

Maureen M Jonas, Robert H Squires, Susan M Rhee, Chih-Wei Lin, Kazuhiko Bessho, Cornelia Feiterna-Sperling, Loreto Hierro, Deirdre Kelly, Simon C Ling, Tatiana Strokova, Antonio Del Valle-Segarra, Sandra Lovell, Wei Liu, Teresa I Ng, Ariel Porcalla, Yuri Sanchez Gonzalez, Margaret Burroughs, Etienne Sokal, Maureen M Jonas, Robert H Squires, Susan M Rhee, Chih-Wei Lin, Kazuhiko Bessho, Cornelia Feiterna-Sperling, Loreto Hierro, Deirdre Kelly, Simon C Ling, Tatiana Strokova, Antonio Del Valle-Segarra, Sandra Lovell, Wei Liu, Teresa I Ng, Ariel Porcalla, Yuri Sanchez Gonzalez, Margaret Burroughs, Etienne Sokal

Abstract

The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin. A pangenotypic regimen for pediatric patients remains an unmet need. DORA is an ongoing phase 2/3, nonrandomized, open-label study evaluating the pharmacokinetics (PK), safety, and efficacy of G/P in pediatric patients with chronic HCV. This analysis includes Part 1 of the study, conducted in adolescent patients 12-17 years of age given the adult regimen of G/P (300 mg/120 mg) once daily for 8-16 weeks according to the indication durations used in adults. Patients were either treatment naïve or experienced with interferon-based regimens. The primary PK endpoint was steady-state exposures for glecaprevir and pibrentasvir; the primary efficacy endpoint was sustained virologic response 12 weeks after treatment (SVR12). The secondary efficacy endpoints were on-treatment virologic failure, relapse, and reinfection. Safety and tolerability were monitored. Part 1 enrolled 48 adolescent patients infected with genotypes 1, 2, 3, or 4, of whom 47 were administered G/P. All 47 patients (100%) achieved SVR12. No on-treatment virologic failures or relapses occurred. PK exposures of glecaprevir and pibrentasvir were comparable to exposures in adults. No adverse events (AEs) led to treatment discontinuation, and no serious AEs occurred. Conclusion: Adolescent patients with chronic HCV infection treated with G/P achieved a comparable exposure to adults, 100% SVR12 rate, and safety profile consistent with that in adults. This pangenotypic regimen demonstrated 100% efficacy within the adolescent population in as little as 8 weeks of treatment.

Trial registration: ClinicalTrials.gov NCT03067129.

© 2019 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.

References

    1. Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505‐515.
    1. HARVONI (ledipasvir and sofosbuvir) prescribing information. Foster City, CA: Gilead Sciences; 2015.
    1. SOVALDI (sofosbuvir) tablets, for oral use [package insert]. Foster City, CA: Gilead Sciences.
    1. Mavyret (glecaprevir/pibrentasvir) prescribing information. AbbVie, Inc.; 2017.
    1. Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8‐week and 12‐week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol 2018;69:293‐300.
    1. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION‐1): a single‐arm, open‐label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062‐1068.
    1. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION‐2 study. Clin Infect Dis 2018;67:1010‐1017.
    1. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 2018;67:514‐523.
    1. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology 2018;67:1253‐1260.
    1. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800‐812.
    1. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003;3:329‐341.
    1. Centers for Disease Control and Prevention . Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep 2018;67:634‐642.
    1. World Health Organization . Influenza update. January 8, 2018.
    1. Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827‐831.
    1. Wirth S, Pieper‐Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa‐2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013‐1018.
    1. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir‐sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371‐378.
    1. Wirth S, Rosenthal P, Gonzalez‐Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102‐1110.
    1. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017;1:87‐98.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅